Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
Clinical trial NCT02760433 · COMPLETED
Trial details
- NCT number
- NCT02760433
- Sponsor
- R-Pharm International, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-25
- Primary completion
- 2019-09-12
- Enrollment
- 368
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.